Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK.
- DOI
- 10.1002/cpt.70284
- Published
- 2026-04-14
- Container
- Clin Pharmacol Ther
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cpt.70284,
title = {Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK.},
author = {Dong J and Moir A and Pepin X and Lowe E and Hopkins S and Tang W and Zhou D.},
year = {2026},
journal = {Clin Pharmacol Ther},
doi = {10.1002/cpt.70284},
url = {https://doi.org/10.1002/cpt.70284}
}RIS
TY - JOUR TI - Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK. AU - Dong J AU - Moir A AU - Pepin X AU - Lowe E AU - Hopkins S AU - Tang W AU - Zhou D. PY - 2026 JO - Clin Pharmacol Ther DO - 10.1002/cpt.70284 UR - https://doi.org/10.1002/cpt.70284 ER -
APA
J, D., A, M., X, P., E, L., S, H., W, T., & D., Z. (2026). Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK.. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.70284
Source records
- europe-pmc · retrieved 2026-09-25T05:11:34.934Z